Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
- Conditions
- Interventions
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 102
- Registration Number
- NCT04317105
- Locations
- 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
🇨🇦University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation
- Conditions
- Interventions
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- University of Utah
- Registration Number
- NCT04315155
A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 21
- Registration Number
- NCT04311710
- Locations
- 🇳🇿
Local Institution - 0010, Auckland, New Zealand
🇺🇸Local Institution - 0013, Fort Wayne, Indiana, United States
🇮🇹Istituto Nazionale Tumori IRCCS Fondazione Pascale-s.c. melanoma, immunoterapia oncologica e terapie, Napoli, Italy
CIML NK Cell in Head & Neck Cancer
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT04290546
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 25
- Registration Number
- NCT04270864
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Herlev Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT04258150
- Locations
- 🇩🇰
Herlev & Gentofte University Hospital, Denmark, Herlev, Denmark
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2024-06-07
- Target Recruit Count
- 56
- Registration Number
- NCT04248569
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Herlev Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04247165
- Locations
- 🇩🇰
Herlev & Gentofte University Hospital, Denmark, Herlev, Denmark
GVAX Plus Checkpoint Blockade in Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT04239040
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institite, Boston, Massachusetts, United States
A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 10
- Registration Number
- NCT04196452
- Locations
- 🇺🇸
Local Institution, Princeton, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.